273 related articles for article (PubMed ID: 14583476)
1. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates.
Xiang Y; Wang Z; Murakami J; Plummer S; Klein EA; Carpten JD; Trent JM; Isaacs WB; Casey G; Silverman RH
Cancer Res; 2003 Oct; 63(20):6795-801. PubMed ID: 14583476
[TBL] [Abstract][Full Text] [Related]
2. HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
Malathi K; Paranjape JM; Ganapathi R; Silverman RH
Cancer Res; 2004 Dec; 64(24):9144-51. PubMed ID: 15604285
[TBL] [Abstract][Full Text] [Related]
3. A transcriptional signaling pathway in the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L.
Malathi K; Paranjape JM; Bulanova E; Shim M; Guenther-Johnson JM; Faber PW; Eling TE; Williams BR; Silverman RH
Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14533-8. PubMed ID: 16203993
[TBL] [Abstract][Full Text] [Related]
4. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1.
Carpten J; Nupponen N; Isaacs S; Sood R; Robbins C; Xu J; Faruque M; Moses T; Ewing C; Gillanders E; Hu P; Bujnovszky P; Makalowska I; Baffoe-Bonnie A; Faith D; Smith J; Stephan D; Wiley K; Brownstein M; Gildea D; Kelly B; Jenkins R; Hostetter G; Matikainen M; Schleutker J; Klinger K; Connors T; Xiang Y; Wang Z; De Marzo A; Papadopoulos N; Kallioniemi OP; Burk R; Meyers D; Grönberg H; Meltzer P; Silverman R; Bailey-Wilson J; Walsh P; Isaacs W; Trent J
Nat Genet; 2002 Feb; 30(2):181-4. PubMed ID: 11799394
[TBL] [Abstract][Full Text] [Related]
5. The association of elevated 2',5'-oligoadenylate-dependent RNase L with lung cancer correlated with deficient enzymatic activity and decreased capacity of RNase L dimerization.
Yin H; Zhou A; Dai Y
Lung Cancer; 2012 Oct; 78(1):30-8. PubMed ID: 22925698
[TBL] [Abstract][Full Text] [Related]
6. [RNase L, a crucial mediator of innate immunity and other cell functions].
Bisbal C; Salehzada T
Med Sci (Paris); 2008 Oct; 24(10):859-64. PubMed ID: 18950583
[TBL] [Abstract][Full Text] [Related]
7. Implications for RNase L in prostate cancer biology.
Silverman RH
Biochemistry; 2003 Feb; 42(7):1805-12. PubMed ID: 12590567
[TBL] [Abstract][Full Text] [Related]
8. RNase L is a negative regulator of cell migration.
Banerjee S; Li G; Li Y; Gaughan C; Baskar D; Parker Y; Lindner DJ; Weiss SR; Silverman RH
Oncotarget; 2015 Dec; 6(42):44360-72. PubMed ID: 26517238
[TBL] [Abstract][Full Text] [Related]
9. 5'-O-dephosphorylated 2',5'-oligoadenylate (2-5A) with 8-methyladenosine at the 2'-terminus activates human RNase L.
Nagaoka K; Kitamura Y; Ueno Y; Kitade Y
Bioorg Med Chem Lett; 2010 Feb; 20(3):1186-8. PubMed ID: 20022497
[TBL] [Abstract][Full Text] [Related]
10. Caspase-dependent apoptosis by 2',5'-oligoadenylate activation of RNase L is enhanced by IFN-beta.
Rusch L; Zhou A; Silverman RH
J Interferon Cytokine Res; 2000 Dec; 20(12):1091-100. PubMed ID: 11152576
[TBL] [Abstract][Full Text] [Related]
11. Controlling gene expression with 2-5A antisense.
Leaman DW; Cramer H
Methods; 1999 Jul; 18(3):252-65. PubMed ID: 10454983
[TBL] [Abstract][Full Text] [Related]
12. RNase L dimerization in a mammalian two-hybrid system in response to 2',5'-oligoadenylates.
Naik S; Paranjape JM; Silverman RH
Nucleic Acids Res; 1998 Mar; 26(6):1522-7. PubMed ID: 9490801
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, characterization, and biological properties of 8-azido- and 8-amino-substituted 2',5'-oligoadenylates.
Sawai H; Hirano A; Mori H; Shinozuka K; Dong B; Silverman RH
J Med Chem; 2003 Nov; 46(23):4926-32. PubMed ID: 14584943
[TBL] [Abstract][Full Text] [Related]
14. 2-5A-dependent RNase molecules dimerize during activation by 2-5A.
Dong B; Silverman RH
J Biol Chem; 1995 Feb; 270(8):4133-7. PubMed ID: 7876164
[TBL] [Abstract][Full Text] [Related]
15. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer.
Wiklund F; Jonsson BA; Brookes AJ; Strömqvist L; Adolfsson J; Emanuelsson M; Adami HO; Augustsson-Bälter K; Grönberg H
Clin Cancer Res; 2004 Nov; 10(21):7150-6. PubMed ID: 15534086
[TBL] [Abstract][Full Text] [Related]
16. The missense mutations in the candidate prostate cancer gene ELAC2 do not alter enzymatic properties of its product.
Minagawa A; Takaku H; Takagi M; Nashimoto M
Cancer Lett; 2005 May; 222(2):211-5. PubMed ID: 15863270
[TBL] [Abstract][Full Text] [Related]
17. A convenient and sensitive fluorescence resonance energy transfer assay for RNase L and 2',5' oligoadenylates.
Thakur CS; Xu Z; Wang Z; Novince Z; Silverman RH
Methods Mol Med; 2005; 116():103-13. PubMed ID: 16000857
[TBL] [Abstract][Full Text] [Related]
18. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases.
Casey G; Neville PJ; Plummer SJ; Xiang Y; Krumroy LM; Klein EA; Catalona WJ; Nupponen N; Carpten JD; Trent JM; Silverman RH; Witte JS
Nat Genet; 2002 Dec; 32(4):581-3. PubMed ID: 12415269
[TBL] [Abstract][Full Text] [Related]
19. Comparative study on the biological properties of 2',5'-oligoadenylate derivatives with purified human RNase L expressed in E. coli.
Yoshimura A; Nakanishi M; Yatome C; Kitade Y
J Biochem; 2002 Oct; 132(4):643-8. PubMed ID: 12359081
[TBL] [Abstract][Full Text] [Related]
20. 2-5A induces a conformational change in the ankyrin-repeat domain of RNase L.
Nakanishi M; Goto Y; Kitade Y
Proteins; 2005 Jul; 60(1):131-8. PubMed ID: 15849753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
